Word count of the text: 3357 Highlights  Patients of febrile status epilepticus have high mortality and morbidity.  IVIG combined steroid pulse therapy is associated with better outcomes of febrile status epilepticus.  We suggest early and aggressive immunotherapy for febrile status epilepticus. refractory status epilepticus was associated with better neurological and seizure outcomes. Further prospective studies are needed to confirm these findings.
Results:
We enrolled 63 patients (38 boys), aged 1 to 18 years, all of whom received multiple antiepileptic drugs. Twenty-nine (46%) of the patients received intravenous immunoglobulin alone, 16 (25.4%) received a combination of intravenous immunoglobulin and methylprednisolone pulse therapy, and 18 (28.6%) did not receive immunotherapy treatment. Overall, 12 (19%) patients died within 1 month. After 6 months, 12 (20%) patients had good neurological outcomes, including two who returned to baseline and 13 (29.5%) who had favourable seizure outcomes. We compared the outcomes of the different treatments, and found that a combination of intravenous immunoglobulin and methylprednisolone pulse therapy had the best neurological and seizure outcomes at 6 months compared to intravenous immunoglobulin alone and no immunotherapy.
Conclusions:
Our observational study showed that a combination of intravenous immunoglobulin and methylprednisolone pulse therapy as adjuvant treatment for febrile A C C E P T E D M A N U S C R I P T Lin 4 refractory status epilepticus was associated with better neurological and seizure outcomes. Further prospective studies are needed to confirm these findings.
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Introduction
Refractory status epilepticus is a state of persistent seizures lasting more than 2 hours despite optimal treatment with antiepileptic drugs. 1 It is a neurological emergency which can cause severe neurological sequelae, and even death. There are various causes of paediatric refractory status epilepticus, some of which are febrile related. [2] [3] [4] Immunemediated mechanisms and inflammatory processes may play a role in determining or contributing to neurological manifestations in such patients. 2, 5 Nevertheless, it is difficult to differentiate the aetiology in the first 1 to 2 days of refractory status epilepticus.
Regarding the pathogenesis, increasing evidence suggests that acute brain inflammation caused by fever and status epilepticus can lead to persistent brain excitability, which may then contribute to refractory status epilepticus. 2, 6 Subsequently, persistent refractory status epilepticus-induced chronic brain inflammation may contribute to further epileptogenesis. 7 In addition, experimental evidence has shown that brain inflammation is caused by the activation of interleukin-1 receptor/toll-like receptor pathways. 6, 7 Preliminary clinical observations have also suggested a likely vicious cycle involving inflammation and seizure activity in status epilepticus, the so called "acute encephalopathy with inflammation-mediated status epilepticus". 5 Furthermore, encephalitis has been reported to be accompanied by different levels of inflammatory cytokines in the brain. 2 Therefore, modulating immune disturbance and inflammatory processes may be important in managing febrile refractory status epilepticus.
Accumulating evidence supports the combined use of anti-inflammatory and antiepileptic drugs to reduce brain inflammation, which may then decrease seizure burden in refractory status epilepticus and subsequent epileptogenesis. 8, 9 However, studies on the
use of intravenous immunoglobulin (IVIG) and methylprednisolone pulse therapy as adjuvant treatment of febrile status epilepticus are lacking, and only a few case reports have been published. [9] [10] [11] [12] [13] [14] [15] [16] The early and aggressive application of immunotherapy in such patients may facilitate a faster recovery, 10, 11 however it remains unclear whether or not a combination of IVIG and methylprednisolone pulse therapy is superior to IVIG alone.
The aim of this retrospective study was to investigate the effects of different immunotherapies for the management of children with febrile refractory status epilepticus in the acute stage. In order to include diverse aetiologies, we focused on previously healthy children who presented with febrile refractory status epilepticus, and excluded those positive for antineuronal antibodies against surface antigens which are well-known to be immunotherapy-responsive.
Material and methods
Refractory status epilepticus is defined as seizures lasting more than 2 hours despite optimal treatment, including initial therapy with benzodiazepine followed by intravenous antiepileptic drugs such as phenytoin, phenobarbital, valproate or levetiracetam. 1, 3, 4 Super-refractory status epilepticus is defined as status epilepticus that continues or recurs 24 hours or more after the initiation of anaesthetic therapy, including cases where status epilepticus recurs with the reduction or withdrawal of anaesthesia 1 . Febrile refractory status is defined as fever and refractory status epilepticus. Encephalitis is defined as the presence of encephalopathy plus at least two of the following: 1) fever; 2) cerebrospinal fluid evidence of neuroinflammation; 3) abnormal electroencephalography findings; and 4) abnormal radiologic evidence. 3, 4 We retrospectively reviewed paediatric patients admitted to the paediatric intensive hours after hospitalization. Methylprednisolone was given as high-dose pulse therapy (30 mg/kg/day with a maximum of 1000 mg/day) for the initial 3 days, followed by a maintenance dose of 1 mg/kg every 6 hours for 4 days, and then tapered down in 1 week.
The clinical features, treatment and outcomes were recorded. We then divided the patients into three groups: those who received a combination of IVIG and methylprednisolone pulse therapy, those who received IVIG alone, and those who did not receive immunotherapy. The primary outcomes were neurological and seizure outcomes after 6 months of evaluation. The secondary outcome was the hospital course, including
paediatric intensive care unit stay, duration of hospitalization, and 1-month mortality rate.
The neurological and seizure outcomes were determined at 6 months after the first episode of status epilepticus. Neurological outcomes were evaluated according to the Pediatric Cerebral Performance Score. We defined a Pediatric Cerebral Performance Score of less than or equal to 2 as a good outcome, and greater than or equal to 3 as a bad outcome. 17 All of the patients were treated with antiepileptic drugs at discharge. Seizure outcomes were categorized into two groups after 6 months of follow-up: (1) intractable epilepsy, defined as more than two seizures per month in patients taking two or more antiepileptic drugs; and (2) favourable outcome, defined as being either seizure free or having fewer than two seizures per month after treatment. 4 The hospital's Institutional
Review Board approved this study (104-2573B, 201701354B0).
Statistical analysis
The primary and secondary outcomes were analyzed and compared between those who received a combination of IVIG and methylprednisolone pulse therapy, those who received IVIG alone, and those who did not receive immunotherapy. All statistical analyses were performed using SPSS statistical software, version 19.0 (SPSS Inc., Chicago, IL, USA). Descriptive data were presented as mean±standard deviation (SD) or percentage. The Mann-Whitney U test and Kruskal-Wallis test were used for continuous variables, and the chi-square or Fisher's exact test was used for categorical variables. A p value of less than 0.05 was considered to be statistically significant. All statistical tests were two-tailed.
Results

A C C E P T E D M
A N U S C R I P T Lin 9 In total, 68 previously healthy children diagnosed with febrile refractory status epilepticus were admitted to our paediatric intensive care unit during the study period. Of these 68 patients, 63 were included in this study, including 25 girls (39.7%) and 38 boys (60.3%), with a mean (± SD) age at presentation of 8. (Table 1) .
3.1.Treatment, hospital course and outcome
All patients received multiple antiepileptic drugs to control their seizures. In
addition, all of the patients received empiric antibiotics and acyclovir before an infectious aetiology was excluded, and all of them were intubated with or without inotropic agents.
We used the number of anti-epileptic drugs as the intensity of therapy. All of the survivors (n=51) were discharged with anti-epileptic drugs. Twenty-seven children had re-admission due to uncontrolled seizures after the first admission, including 4 children presented with recurrent status epilepticus during the follow-up period. After 6 months of follow-up, three patients were lost to follow-up and four patients died. Twelve (20%) of the patients had good neurological outcomes and, 13 (29.5%) had favourable seizure outcomes. In the combination of IVIG and methylprednisolone pulse therapy group, seven patients (43.8%) had a good neurological outcome at 6 months (Pediatric Cerebral Performance Score ≤ 2) including two who returned to baseline, and nine (56.2%) had a bad outcome (Pediatric Cerebral Performance Score ≥3), including two who died within 1 month and two who died due to sepsis during the follow-up period.
Twelve of these children were followed for more than 6 months, at the end of which seven (58.3%) had favourable seizure outcomes, and five (41.7%) had intractable
seizures. In the IVIG group, one patient was lost to follow-up. Three patients (10.7%) had a good neurological outcome, and 25 (89.3%) had a bad outcome, including eight who died within 1 month and two who died due to sepsis during the follow-up period.
Eighteen of these children were followed for more than 6 months, at the end of which 14 (77.8%) had intractable seizures, and 4 (22.2%) had favourable seizure outcomes. In the group who did not receive immunotherapy, two patients were lost to follow-up. Two patients (12.5%) had a good neurological outcome at 6 months and 14 (87.5%) had a bad outcome, including two who died within 1 month. Fourteen of these children were followed for more than 6 months, at the end of which 12 (85.7%) had intractable seizures, and 2 (14.3%) had favourable seizure outcomes (Supplemental table 1).
Comparison of the groups who received a combination of IVIG and methylprednisolone pulse therapy, IVIG alone and no immunotherapy
Comparisons of different treatments and outcomes of the patients with febrile refractory status epilepticus are summarized in Table 2 . The patients in the combination of IVIG and methylprednisolone pulse therapy group had significantly better neurological and seizure outcomes at 6 months than the IVIG alone and no immunotherapy groups (Table 2 ). However, there was no significant difference between the IVIG alone and no immunotherapy groups in neurological and seizure outcomes at 6 months. In addition, the combination of IVIG and methylprednisolone pulse therapy group had a lower 1-month mortality rate than the IVIG alone group (12.5% vs. 27.6%), although without statistical significance (Table 2 ). In addition, the combination of IVIG and methylprednisolone pulse therapy group had a significantly shorter duration of Supplemental table 3 ). Besides, we used univariate regression analyses, including seizure severity, number of anti-epileptic drugs, year of admission, and treatment group, for each of the primary outcome and used multivariate regression analyses for each of the primary outcome that includes only variables significant at the p<0.1 level in univariate analyses. The results showed no statistical significance by using multivariate regression analyses for admission year and treatment group (Table 3) .
Discussion
Treating children with febrile refractory status epilepticus is a challenge in a paediatric intensive care unit, and high mortality and morbidity rates have been reported. 6, 7, 11 Recently, increasing evidence has suggested that an immune-mediated mechanism and inflammatory processes may play a role in this disease and subsequent
A C C E P T E D M
A N U S C R I P T Lin 13 epileptogenesis. 2, 5 Furthermore, excitability changes in the neuronal network that occur during status epilepticus and the occurrence of encephalitis have both been reported to increase the levels of brain inflammatory cytokines, which may then contribute to further status epilepticus and subsequent epileptogenesis. 6 Theoretically, earlier aggressive immunotherapy in such patients may reduce brain inflammation and decrease seizure burden in the acute stage of status epilepticus and subsequent epileptogenesis, 8, 9 and thereby facilitate a faster recovery. under the consensus of a paediatric intensive care unit treatment protocol. The initial rationale was to inhibit fever and encephalitis-related inflammatory cytokine-induced cerebral oedema. 18 In 2009, we modified this protocol to a combination of IVIG and methylprednisolone pulse therapy. Therefore, we retrospectively compared the effects of using IVIG alone or a combination of IVIG and methylprednisolone pulse therapy as adjuvant treatment of febrile refractory status epilepticus. We found better neurological and seizures outcomes at 6 months in the combination of IVIG and methylprednisolone pulse therapy group than the IVIG alone and no immunotherapy groups, and a shorter hospitalization in the combination of IVIG and methylprednisolone pulse therapy group compared to the IVIG alone group. In addition, we also found that in the patients with refractory status epilepticus, those who received a combination of IVIG and methylprednisolone pulse therapy had significantly better neurological and seizure outcomes than those who received IVIG alone and those who did not receive immunotherapy. Nevertheless, the association between treatment group and outcome observed in univariate analysis is not apparent in the multivariable analysis after adjusting for year of admission. Therefore, it is difficult to distinguish the benefit of aggressive immunotherapy from improvement of critical care management by years.
There may be confounding factors in this study, such as greater availability of continuous electroencephalogram monitoring, or the better timelines of anti-seizure treatment in intensive care unit after 2009.
The rates of morbidity and mortality due to refractory status epilepticus in children are highest in those with an acute symptomatic aetiology, of which encephalitis is the
most common. 6, 7, 19 In a meta-analysis of refractory status epilepticus in children, the mortality rate was 20%, and no child with acute symptomatic refractory status epilepticus returned to baseline. [19] [20] In our study, the overall 1-month mortality rate (19%) is consistent with previous studies. However, we found better 6-month neurological and seizure outcomes in the combination of IVIG and methylprednisolone pulse therapy group, including two patients who returned to baseline. Therefore, aggressive immunotherapy with a combination of IVIG and methylprednisolone pulse therapy might play a role in the management of febrile refractory status epilepticus. Further prospective large-scale studies are warranted to validate our findings.
There are several limitations to this study. First, this is a retrospective study.
Assessing the effects of immunotherapy as adjuvant treatment in the acute stage was difficult because all patients received multiple therapies for refractory status epilepticus.
Lack of available information on clinical and electroencephalographic seizure duration is a part of limitation in our study. Second, there are limited data of methylprednisolone pulse therapy alone in our study. Further study is necessary to compare the effect of methylprednisolone pulse therapy alone and the combination of IVIG and methylprednisolone pulse therapy. Third, the aim of this study was to investigate the effects of immunotherapy on immune disturbances and inflammatory processes in children with febrile refractory status epilepticus. However, we did not check immunerelated profiles such as cytokines or other immune biomarkers. Fourth, the outcome of refractory status epilepticus fundamentally depends on the underlying aetiology. We focused on previously healthy children with febrile refractory status epilepticus and excluded those positive for antineuronal antibodies against surface antigens. In our
hospital, we were unable to check antineuronal antibodies before 2009, and so some of these patients may have had autoimmune encephalitis. Therefore, we could not differentiate some cases with autoimmune encephalitis who may have responded well to immunotherapy before 2009. Fifth, there was a limited number of patients in each group.
However, to the best of our knowledge, this is the largest cohort to investigate IVIG and methylprednisolone pulse therapy in children with febrile refractory status epilepticus.
Sixth, 27 children were re-admitted for uncontrolled seizures, including 4 for recurrent status epilepticus. The outcomes could be influenced by these recurrent episodes of status epilepticus. Seventh, this is a retrospective observational study. The results showed the association of combination therapy with better outcomes. Nevertheless, no conclusions can be drawn about the superior efficacy of one therapy versus another.
Conclusions
Febrile status epilepticus is the most common type of status epilepticus in children. Patients with refractory status epilepticus have high rates of mortality and morbidity. Immune-mediated mechanisms and inflammatory processes seem to play an important role in disease severity and epileptogenesis. Our retrospective observational study showed that the patients who received a combination of IVIG and methylprednisolone pulse therapy were associated with better neurological and seizure outcomes at 6 months than those who received IVIG alone and those who did not receive immunotherapy, and a shorter hospitalization than those who received IVIG alone.
Nevertheless, it is difficult to distinguish the benefit of aggressive immunotherapy from improvement of critical care management by years. Further prospective studies are Lin 17 needed to confirm these findings. In the combined IVIG and methylprednisolone pulse therapy group, no patient was lost to follow-up and two patients died during the followup period. In the IVIG group, one patient was lost to follow-up and two patients died during the follow-up period. In the no treatment group, two patients were lost to follow-up, and no patient died during the follow-up period. # : The patients with 6-month neurological outcomes including those who died within 1 month, but excluding those who were lost to follow-up.
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